Table 2 Top ten most frequently reported AEs of NK-1RAs at the PT level.

From: Analyzing the adverse events of NK-1 receptor antagonists: a pharmacovigilance study from the FAERS database

Rank

APR

FAP

RP

PTs

n

ROR

(95%CI lower limit)

χ2

IC

(IC025)

EBGM

(EBGM05)

PTs

n

ROR(95%CI lower limit)

χ2

IC

(IC025)

EBGM

(EBGM05)

PTs

n

ROR

(95%CI lower limit)

χ2

IC

(IC025)

EBGM

(EBGM05)

1

Dyspnoea

378

3.46

763.93

0.23

3.43

Dyspnoea

139

3.80

363.06

0.46

3.78

Death

241

7.59

1453.00

1.30

6.99

2

Flushing

267

12.64

3205.79

2.13

12.57

Flushing

112

15.85

1859.81

2.54

15.82

Flushing

92

29.53

3026.10

3.45

29.23

3

Erythema

180

4.06

515.54

0.55

4.10

Pyrexia

87

3.70

237.47

0.50

3.76

Dyspnoea

73

3.06

150.11

0.25

3.10

4

Back pain

163

3.31

340.28

0.27

3.35

Infusion related reaction

75

17.52

1470.91

2.76

17.79

Infusion related reaction

64

22.51

1668.18

3.14

22.74

5

Hypersensitivity

138

3.52

327.42

0.38

3.58

Erythema

54

3.42

143.21

0.48

3.53

Erythema

56

5.64

299.48

1.18

5.76

6

Infusion related reaction

119

9.10

1056.00

1.76

9.26

Neutropenia

54

5.59

289.65

1.18

5.76

Feeling hot

47

18.73

1058.15

2.94

19.19

7

Chest discomfort

114

5.40

523.22

1.02

5.51

Chest discomfort

54

7.49

419.97

1.61

7.71

Hospitalisation

35

4.04

131.52

0.81

4.21

8

Adverse event

113

5.70

559.55

1.10

5.82

Back pain

52

2.97

110.87

0.28

3.07

Back pain

32

2.79

69.71

0.30

2.92

9

Anaphylactic reaction

108

10.12

1100.57

1.93

10.32

Constipation

49

3.18

118.77

0.40

3.30

Chest discomfort

30

6.29

211.02

1.49

6.59

10

Infusion site pain

79

28.68

2632.54

3.47

29.29

Febrile neutropenia

44

9.24

456.65

1.95

9.58

Abdominal discomfort

29

3.14

78.67

0.50

3.30

Back to article page